Targeted human papillomavirus vaccination of men who have sex with men in the USA: A cost-effectiveness modelling analysis

The Lancet Infectious Diseases

Volumn 10, Issue 12, 2010, Pages 845-852

  Kim, Jane J ^a  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

AGE; ANUS CANCER; ARTICLE; CANCER INCIDENCE; CONDYLOMA ACUMINATUM; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; HIGH RISK POPULATION; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 6; MALE HOMOSEXUAL; PREVALENCE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY ANALYSIS; STATISTICAL ANALYSIS; SURVIVAL RATE; UNITED STATES; VACCINATION;

ADOLESCENT; ADULT; AGE FACTORS; ANUS NEOPLASMS; CHILD; COHORT STUDIES; COMPUTER SIMULATION; CONDYLOMATA ACUMINATA; COST-BENEFIT ANALYSIS; HOMOSEXUALITY, MALE; HUMANS; IMMUNIZATION; MALE; MARKOV CHAINS; MODELS, ECONOMIC; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; UNITED STATES; YOUNG ADULT;

EID: 78649449572     PISSN: 14733099     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1473-3099(10)70219-X     Document Type: Article

References (41)

1. Cancer facts and figures American Cancer Society, (accessed June 28, 2010). http://www.cancer.org/acs/groups/content/@nho/documents/document/cff2009estcd3pdf.pdf.
2. Franceschi S, De Vuyst H Human papillomavirus vaccines and anal carcinoma. Curr Opin HIV AIDS 2009, 4:57-63.
3. Palefsky JM Human papillomavirus-related disease in men: not just a women's issue. J Adolesc Health 2010, 46(suppl 1):S12-S19.
4. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet 2007, 369:1861-1868. The Future II Study Group.
5. Garland SM, Hernandez-Avila M, Wheeler CM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007, 356:1928-1943.
6. Paavonen J, Naud P, Salmeron J, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009, 374:301-314. for the HPV PATRICIA Study Group.
7. De Carvalho N, Teixeira J, Roteli-Martins CM, et al. Sustained efficacy and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine up to 7.3 years in young adult women. Vaccine 2010, 28:6247-6255.
8. Dillner J, Kjaer SK, Wheeler CM, et al. Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial. BMJ 2010, 341:c3493.
9. Saslow D, Castle PE, Cox JT, et al. American Cancer Society Guideline for human papillomavirus (HPV) vaccine use to prevent cervical cancer and its precursors. CA Cancer J Clin 2007, 57:7-28.
10. Markowitz LE, Dunne EF, Saraiya M, Lawson HW, Chesson H, Unger ER Quadrivalent human papillomavirus vaccine: recommendations of the advisory committee on immunization practices (ACIP). MMWR Recomm Rep 2007, 56:1-24.
11. Giuliano AR, Palefsky J The efficacy of quadrivalent HPV (types 6/11/16/18) vaccine in reducing the incidence of HPV-related genital disease in young men (accessed June 30, 2010). http://www.eurogin.com/2008/EUROGIN2008_LastMinuteAbstracts.pdf.
12. Palefsky J, Giuliano AR Efficacy of the quadrivalent HPV vaccine against HPV 6/11/16/18-related genital infection in young men. EUROGIN (accessed June 30, 2010). http://www.eurogin.com/2008/EUROGIN2008_LastMinuteAbstracts.pdf.
13. FDA licensure of quadrivalent human papillomavirus vaccine (HPV4, Gardasil) for use in males and guidance from the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2010, 59:630-632. Centers for Disease Control and Prevention.
14. Palefsky J. Efficacy of the quadrivalent HPV vaccine to prevent anal intraepithelial neoplasia among young men who have sex with men. 26th International Papillomavirus Conference; Montreal, Canada; July 3-8, 2010.
15. Kim JJ, Goldie SJ Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States. BMJ 2009, 339:b3884.
16. Jit M, Choi YH, Edmunds WJ Economic evaluation of human papillomavirus vaccination in the United Kingdom. BMJ 2008, 337:a769.
17. Simatherai D, Bradshaw CS, Fairley CK, Bush M, Heley S, Chen MY What men who have sex with men think about the human papillomavirus vaccine. Sex Transm Infect 2009, 85:148-149.
18. Seaberg EC, Wiley D, Martinez-Maza O, et al. Cancer incidence in the multicenter aids cohort study before and during the HAART era: 1984 to 2007. Cancer 2010, published online July 29. 10.1002/cncr.25530.
19. D'Souza G, Wiley DJ, Li X, et al. Incidence and epidemiology of anal cancer in the multicenter AIDS cohort study. J Acquir Immune Defic Syndr 2008, 48:491-499.
20. Surveillance, epidemiology, end results (SEER) cancer statistics review, 1975-2001 US National Cancer Institute, (accessed Oct 1, 2010). http://seer.cancer.gov/csr/1975_2001/.
21. Bower M, Powles T, Newsom-Davis T, et al. HIV-associated anal cancer: has highly active antiretroviral therapy reduced the incidence or improved the outcome?. J Acquir Immune Defic Syndr 2004, 37:1563-1565.
22. Gold MR, Franks P, McCoy KI, Fryback DG Toward consistency in cost-utility analyses: using national measures to create condition-specific values. Med Care 1998, 36:778-792.
23. Hu D, Goldie SJ The economic burden of noncervical human papillomavirus disease in the United States. Am J Obstet Gynecol 2008, 198:e1-e7.
24. Giuliano AR Incidence of genital warts among men in the placebo arm of a quadrivalent HPV vaccine efficacy trial (accessed June 27, 2010). http://cdc.confex.com/cdc/std2010/webprogram/Paper21440.html.
25. Insinga RP, Dasbach EJ, Myers ER The health and economic burden of genital warts in a set of private health plans in the United States. Clin Infect Dis 2003, 36:1397-1403.
26. Lacey CJ, Lowndes CM, Shah KV Chapter 4: burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease. Vaccine 2006, 24(Suppl 3):S35-S41.
27. Myers ER, Green S, Lipkus I. Patient preferences for health states related to HPV infection: visual analogue scales versus time trade-off elicitation. Proceedings of the 21st International Papillomavirus Conference; Mexico City, Mexico; Feb 20-26, 2004. (abstr).
28. Fryback DG, Dasbach EJ, Klein R, et al. The Beaver Dam Health Outcomes Study: initial catalog of health-state quality factors. Med Decis Making 1993, 13:89-102.
29. Karnon J, Jones R, Czoski-Murray C, Smith KJ Cost-utility analysis of screening high-risk groups for anal cancer. J Public Health (Oxf) 2008, 30:293-304.
30. HIV prevalence, unrecognized infection, and HIV testing among men who have sex with men-five US cities, June 2004-April 2005. MMWR Morb Mortal Wkly Rep 2005, 54:597-601. Centers for Disease Control and Prevention.
31. Xu F, Sternberg MR, Markowitz LE Men who have sex with men in the United States: demographic and behavioral characteristics and prevalence of HIV and HSV-2 infection: results from National Health and Nutrition Examination Survey 2001-2006. Sex Transm Dis 2010, 37:399-405.
32. Hoy T, Singhal PK, Willey VJ, Insinga RP Assessing incidence and economic burden of genital warts with data from a US commercially insured population. Curr Med Res Opin 2009, 25:2343-2351.
33. Cost-effectiveness in health and medicine 1996, Oxford University Press, New York. M.R. Gold, J.E. Siegel, L.B. Russel, M.C. Weinstein (Eds.).
34. Winkelmayer WC, Weinstein MC, Mittleman MA, Glynn RJ, Pliskin JS Health economic evaluations: the special case of end-stage renal disease treatment. Med Decis Making 2002, 22:417-430.
35. Eichler HG, Kong SX, Gerth WC, Mavros P, Jonsson B Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge?. Value Health 2004, 7:518-528.
36. King JT, Tsevat J, Lave JR, Roberts MS Willingness to pay for a quality-adjusted life year: implications for societal health care resource allocation. Med Decis Making 2005, 25:667-677.
37. Shiroiwa T, Sung YK, Fukuda T, Lang HC, Bae SC, Tsutani K International survey on willingness-to-pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness?. Health Econ 2010, 19:422-437.
38. Chin-Hong PV, Vittinghoff E, Cranston RD, et al. Age-specific prevalence of anal human papillomavirus infection in HIV-negative sexually active men who have sex with men: the EXPLORE study. J Infect Dis 2004, 190:2070-2076.
39. Elbasha EH, Dasbach EJ Impact of vaccinating boys and men against HPV in the United States. Vaccine 2010, 28:6858-6867.
40. Woodhall SC, Jit M, Cai C, et al. Cost of treatment and QALYs lost due to genital warts: data for the economic evaluation of HPV vaccines in the United Kingdom. Sex Transm Dis 2009, 36:515-521.
41. Olsson SE, Kjaer SK, Sigurdsson K, et al. Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection. Hum Vaccin 2009, 5:696-704.